“And in fact, this year we should end with somewhere around 140 treatment centers in the U.S., and that will continue to grow in 2024.”

In context

“as soon as we are granted access and reimbursement. And it goes very quickly into the system, because it's a non-fragmented healthcare system. In the U.S., things look a little bit different given the fragmentation of the healthcare system. So the barriers that we're observing in the U.S. are really our ability to treat patients where they are so moving into community oncology. Today, 80% of oncology patients are seen in the community. Most of our authorized treatment centers exist in large academic hospitals. And so what we're doing for the future, and what we think is going to be very important, is that we're able to have authorized treatment centers in the community closer to patients. So that's one important piece. And we continue to open up new treatment centers in the United States. And in fact, this year we should end with somewhere around 140 treatment centers in the U.S., and that will continue to grow in 2024. I think the second piece for barriers is converting stem cell transplants. So physicians who are transplanting patients, they will have a better outcome via the data if they have CAR-T. And so we're working with transplanters on education and really making sure those patients have access to CAR-T in the earlier lines. I think those are two of the larger barriers that we're observing today. And the last piece, I would say, is the excitement with multiple myeloma therapies coming forward. You can imagine the ATCs now we're seeing both lymphoma patients as well as multiple myeloma patients, and that's causing a crunch within those authorized treatment centers. And that's why it's important in the academic medical centers that we're able to expand the number of beds, and secondly, open new au”